FY2023 Separation Roadmap

Combination with Amentum Transaction Structure Shareholders Shareholders Merger Partner / Combined Company Amentum Jacobs amentum > Combined Company 37.0% - 41.5% 51.0% - 55.0%1 Jacobs $1B Cash 7.5% 8.0%¹ 14 NewCo Jacobs CMS/C&I + Amentum 1 Depending on the achievement of certain fiscal year 2024 operating profit targets of the CMS and C&I businesses. ☐ ☐ ■ ☐ ~$7.9B revenue / ~8% Adj. EBITDA margin business >40% focused on high-growth, high margin intel and science and technology sectors Strong momentum in backlog, revenue and profit growth <$4B current net debt at ~8% average interest rate Clients and capabilities very complementary with CMS/C&I $50-70M of expected net cost synergies FY'24 Adj. EBITDA of approximately $1.1B, including expected net cost synergies ~$4.2B expected net debt at close, inclusive of $235M equity contribution from Amentum shareholders and $200M in cash from CMS balance sheet ~3.8x net leverage at closing with clear path to deleveraging below 3x Key Transaction Terms Jacobs Shareholders Jacobs ☐ Governance Amentum Shareholders Timing ■ 51%-55%¹ of combined company shares to be owned by Jacobs shareholders ■ $1B cash dividend at closing 7.5%-8.0%¹ retained stake in combined company (additional value to Jacobs) Retained stake to be disposed of within 12 months of closing Steve Demetriou will serve as Executive Chair of combined company John Heller (current CEO of Amentum) will serve as CEO of combined company Dr. Steve Arnette (EVP and President of CMS) will serve as COO of combined company Initial Board to be split between Jacobs and Amentum nominees Amentum shareholders subject to a 12-month post-closing lock up on shares received in combined company ■ Transaction expected to close in second half of FY2024 Jacobs 2024

View entire presentation